New Software Combines Pre-Op MRI Guidance with Live Ultrasound for Brachytherapy Treatment of Prostate Cancer
The MIM Software HDR Prostate reportedly enables clinicians to utilize preoperative MRI guidance and live ultrasound imaging to enhance tumor visualization during high dose-rate (HDR) brachytherapy treatments for prostate cancer.
Offering an array of imaging-guided benefits for enhancing the precison of brachytherapy treatments for prostate cancer, GE HealthCare has launched MIM Symphony HDR Prostate software at the World Congress of Brachytherapy (July 10-13) in National Harbor, Md.
While computed tomography (CT) and ultrasound are commonly utilized in planning brachytherapy treatments, GE HealthCare said the combination of live ultrasound with preoperative magnetic resonance imaging (MRI) guidance can elevate the precision of high dose-rate (HDR) brachytherapy.
One of the benefits of the MIM Symphony HDR Prostate software is a ReSlicer feature that addresses differences between supine MRI views and ultrasound lithotomy procedures, according to GE HealthCare, the manufacturer of the software. (Image courtesy of GE HealthCare.)
Emphasizing the capability of MIM Symphony HDR Prostate to facilitate accurate alignment of MRI contours with live ultrasound, the company said key benefits of the software include:
• use of the ReSlicer tool to address differences between supine MRI views and ultrasound lithotomy procedures;
• optimized needle placement that can be utilized even with movement of the prostate during the procedure; and
• automated digitization of needles on planning images.
(Editor’s note: For additional related content on prostate cancer imaging, click here.)
“I often get the question, what is the best imaging modality for planning HDR prostate procedures, ultrasound or CT? My response is always MRI. MRI guidance enables more confident, precise treatments and reduces toxicity to organs at risk. I’ve had the pleasure of providing my patients with precise treatments using MRI guidance in MIM Symphony HDR Prostate, and I look forward to other clinics having the same opportunity,” noted Peter Rossi, M.D., FABS, a radiation oncologist at Valley View Hospital in Glenwood Springs, Colo., and chairman of the board for the American Brachytherapy Society.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
